Bevacizumab (BEV) is a humanized monoclonal antibody targeting all VEGF-A isoforms, which prevents the binding of VEGF to its receptors on vascular endothelial cells leading thus, to the inhibition of tumor growth [4]. Here, VEGFA is linked to neoplasm.